期刊文献+

PCT、超敏C反应蛋白、乳酸在脓毒血症预后评断中的应用价值 被引量:10

Application Value of PCT,hs-CRP and Lactic Acid in the Sepsis Prognosis Judgment
下载PDF
导出
摘要 目的:探讨降钙素原(PCT)、超敏C反应蛋白(hs-CRP)、乳酸检测在脓毒血症诊断与预后中的应用价值。方法:选取2011年1月-2015年10月笔者所在医院确诊为脓毒血症病例70例。根据其严重程度及预后,分为两组,预后良好组,共44例;预后不良组(包括病情明显加重,出现多器官衰竭或者死亡),共26例,监测两组患者治疗前PCT、hs-CRP、乳酸水平,比较两组PCT、hs-CRP、乳酸变化,比较三者在反映病情的严重程度以及判断预后中的关系。结果:两组患者PCT均升高,预后良好组PCT水平较预后不良组偏低,下降较快,预后不良组持续升高;hs-CRP均升高,两组升高比较差异无统计学意义(P>0.05),预后良好组缓慢下降;乳酸在预后良好组水平偏低,而且下降较快,在预后不良组,乳酸水平持续升高。结论:在脓毒血症严重程度判断上,PCT、乳酸优于CRP,PCT、乳酸水平越高,提示脓毒血症病情越重,但两者的下降速度更能反应患者预后。 Objective:To explore the application value of PCT,hs-CRP,Lactic acid in the sepsis prognosis judgment.Method:A total of 70 cases with sepsis were selected from January 2011 to October 2015.Patients were divided into two groups according to prognosis,44 patients with good prognosis were in the first group,another 26 patients with poor prognosis were in the second group.The level of PCT,hs-CRP,lactic acid of two groups before treatment were monitored.PCT,hs-CRP,Lactic acid between two groups were compared after treatment,and the prognosis for sepsis were studied.Result:PCT,lactic acid were elevated between two groups,the level of PCT,lactic acid in the good prognosis group were lower than those in the poor prognosis group,which decreased rapidly,however,they were continued to rise in the poor prognosis group.Hs-CRP were elevated with no obvious difference between two groups,and descented slowly in the good prognosis group.Conclusion:In the diagnostic of sepsis,PCT,lactic acid are superior to hs-CRP.The higher level of PCT and lactic acid,the severer condition in the sepsis,but the decline rate is more reactive with the prognosis of patients.
作者 闫建汶
出处 《中外医学研究》 2016年第14期51-53,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 降钙素原 超敏C反应蛋白 乳酸 脓毒血症 预后 PCT hs-CRP Lactic acid Sepsis Prognosis
  • 相关文献

参考文献11

二级参考文献56

共引文献193

同被引文献103

  • 1陈大庆.新生儿败血症辅助检查评价[J].实用儿科临床杂志,2005,20(2):102-105. 被引量:58
  • 2王瑾,张蓉,邵肖梅.降钙素原在新生儿感染中的应用价值[J].临床儿科杂志,2005,23(2):105-107. 被引量:57
  • 3无.脓毒症的定义、诊断标准、中医证候诊断要点及说明(草案)[J].中华急诊医学杂志,2007,16(8):797-798. 被引量:269
  • 4McPaerlin DA, O'Kennedy ILl. Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations [J]. Expert Rev Mol Diagn, 2014, 14(8): 979-998.
  • 5Kevin DR, Ulf MS. Point-of-care testing in the overcrowded emergency department-can it make a differerce [J].Rooney andSchiling Critical Care, 2014, 18(6):692.
  • 6Norgaard B, Mogensen CB. Blood sample tube transporting system versus point of care technology in an emergency department; effect on time from collection to reporting? A randomized trial [J].Scand J Trauma Resusc Emerg Med, 2012(20):71.
  • 7Malone B. Spotlight on point-of-care testing [D]. AACC Clinical Laboratory News, 2012.
  • 8Scientia Advisors. The point-of-care diagnostics market [M]. Cambridge:MA, USA, 2013.
  • 9Chan CP, Mak WC, Cheung KY, et al. Evidence-based point-of- care diagnostics: current status and emerging technologies [J]. Annu Rev Anal Chem(Palo Alto Calif), 2013(6): 191-211.
  • 10Hart KW, Lindsell C, Ryan R. A time-and-motion study of the processes required to obtain cardiac biomarker assays using central laboratory, near-patient testing, and bedside point-of-care testing[J]. Point Care, 2012(11):62-68.

引证文献10

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部